to facilitate availability of NETSPOT nationally, including Zevacor Pharma Inc., that delivered the NETSPOT injection to Holy Name Medical Center. AAA has partnered with four radiopharmacies in the U.S. in two forms: As a kit for reconstitution using a Ga 68 generator, and as NETSPOT Injection, a ready-to-use dose delivered from a local radiopharmacy in selected metropolitan areas. NETSPOT is currently available in the U.S. In a clinical study, NETSPOT demonstrated the ability to change management decisions regarding patients in 71% of cases previously imaged with Octreoscan.1 Saving just one patient from futile surgery can improve the treatment experience, as well as generate cost savings greater than the cost of providing a year’s worth of NETSPOT injections to every NET patient treated in the same hospital! We are proud to contribute to the introduction of pharmaceutical products that improve patient care, while decreasing healthcare costs.” We believe NETSPOT offers superior sensitivity and accuracy compared to previously available diagnostics for NET patients. Stefano Buono, Chief Executive Officer of AAA said, “ We are very excited to bring NETSPOT, a widely anticipated new imaging product to patients in the U.S. Food and Drug Administration (“FDA”) for the preparation of gallium Ga 68 dotatate for injection, for the localization of somatostatin receptor positive neuroendocrine tumors (“NETs”) in adult and pediatric patients using Positron Emission Tomography (“PET“) at Holy Name Medical Center (“Holy Name”) in Teaneck, NJ. Food and Drug Administration (FDA) for the preparation of. AAA today announced the first administration of NETSPOT, a product recently approved by the U.S. AAA today announced the first administration of NETSPOT, a product recently approved by the U.S.
0 Comments
Leave a Reply. |